7:00 am - 8:00 am
Sponsored by Castle Creek Pharmaceuticals &
Regeneron Healthcare Solutions
7:30 am – 8:30 am
Announcement of WCPD 2021 Location
CASES OF THE YEAR: PART III
9:00 am – 10:30 am
COURSE 5: Atopic Dermatitis: What's New, What's News
Tor Shwayder, Henry Ford Medical Center, USA
Sandipan Dhar, Institute of Child Health, India (chairs)
Atopic dermatitis has tremendous impact on children and their families, not only due to its high frequency of occurrence but also from associated symptoms, complications, and co-morbidities. This session involves expert speakers who will highlight the latest findings in understanding the pathogenesis of this condition and its management. Discussion will include risk factors for disease, including global differences; preventive efforts; workup of concomitant conditions; and therapeutic options. Cases will be used to highlight core issues in care and treatment.
SYMPOSIA 25: Beleaguered by Blisters: Autoimmune Blistering Diseases in Children
Kimberly Morel, Columbia University, USA
Ana Saenz de Cantele, Hospital University De Caracas, Venezuela (chairs)
This session will review clinical presentations of autoimmune bullous dermatoses in children: pemphigus including endemic pemphigus foliaceous (fogo selvagem), bullous pemphigoid and linear IgA dermatosis. Differences between adult and pediatric autoimmune blistering diseases will be discussed. Speakers will summarize a diagnostic algorithm, including diagnostic testing, and discuss a practical approach to treatment of pediatric patients with autoimmune bullous diseases including appropriate screening and follow-up.
SYMPOSIA 26: Histiocytoses and Malignant Skin Disorders
Elena Pope, The Hospital for Sick Children & University of Toronto, Canada
Felipe Velasquez, National Institute of Children's Health, Peru (chairs)
This symposium will focus on reviewing clinical entities in the spectrum of benign (histocytic) and malignant skin proliferations (lymphoma, rhabdomyosarcoma, fibrosarcoma, etc.) focusing on recognition and approach to management.
SYMPOSIA 27: Molecular Testing for Smarties
Virginia Sybert, University of Washington/Group Health Cooperative, USA
Daniel Hohl, University Hospital CHUV, Switzerland (chairs)
This symposium will review several aspects of the inherited disorders of the skin, including the role of somatic mosaicism, the implications of patterned dyspigmentation, the pathway to the discovery of new genodermatoses and genes for old genodermatoses, and the utility and limitations of molecular testing.
10:30 am – 11:00 am
11:00 am – 12:30 pm
COURSE 5: Atopic Dermatitis: What's New, What's News - continued
SYMPOSIA 28: Dermoscopy: The Ideal Looking Glass
Nika Finelt, Hofstra North Shore/LIJ, USA
Ashfaq Marghoob, Memorial Sloan Kettering Skin Cancer Center, USA (chairs)
Dermoscopy is an ideal looking glass for evaluating the pediatric dermatology patient. This noninvasive and fun tool aids in clinical diagnosis while intriguing our young patients. Parents are also comforted that an additional tool is utilized to aid in clinical decision-making. This sesson explores the multiple uses of dermoscopy in pediatric dermatology in evaluating skin growths and cancer screening, inflammatory and infectious conditions, as well as hair disorders.
SYMPOSIA 29: Drug Reactions
Elaine Siegfried, St. Louis University School of Medicine, USA
Daniela Kramer, Hospital Luis Calvo Mackenna-Clínica Alemana, Chile (chair)
There is an enormous variety of cutaneous reactions to drugs, with many different clinical morphologies, including morbilliform, scarlatiniform, papulovesicular, bullous, hyperpigmented and urticarial. Less common but more striking are those featuring vasculitis, lichenoid inflammation, panniculitis and photosensitivity as well as those usually recognized only by dermatologists, e.g. fixed drug and acute generalized erythematous pustulosis. The uncommon, but life-threatening conditions DRESS, Stevens-Johnson syndrome and toxic epidermal necrolysis are among the few dermatologic emergencies. Even though all drugs have the potential to trigger a cutaneous reaction, the most frequent culprits are anticonvulsants, antibiotics, sulfonamides and nonsteroidal anti-inflammatory agents. For a few infamous drugs, epidemiologic data has defined the relative risk of a particular reaction, but for the majority of medications, the risk is unknown. The diagnosis is usually based on clinical suspicion. Evaluation depends on the patient's medication exposure as well as the incidence of reactions to those drugs in the general population. Supportive clues include the patient’s lesional morphology, the relative frequency of reactions with similar morphology in the general population and timing of the eruption in relationship to drug initiation. However, onset of a drug eruption varies from hours to months after ingestion. Withdrawal of the suspected drug can also support the diagnosis, but discontinuation may not result in rapid resolution, and the risk of re-challenge argues against its value in confirming the diagnosis. In this session we will present a wealth of expertise in drug reactions.
SYMPOSIA 30: Primary Viral Skin Infections
Robert Sidbury, Seattle Children's Hospital, USA
Osman Kose, Elos Private Clinic, Turkey (chairs)
Primary viral skin infections in childhood are very common. These infections of the skin may present with varied morphologies, including papules, vesiculobullous lesions, ulcers, and tumors. In this session, we will discuss some common viral infection such as HPV, molluscum, herpes infection.